The Use of Anaferon (Pediatric Formulation) for Prophylaxis of Acute Respiratory Viral Infections in Preschool Children

Abstract

Anaferon (pediatric formulation) reduces the incidence of acute respiratory viral infections in sickly children and children with bronchial asthma and has a positive effect on the course of asthma. The preparation produces an immunomodulating effect (increases initially low IFN-gamma levels and normalizes elevated levels of IL-1beta), stimulates synthesis of IgA and IgG, exhibits cytoprotective activity, and improves local immunity of the upper airways in sickly children.

Adjunctive use of interferon γ inducer for treatment of patients with schizophrenia

“…These data suggest pathogenic justification for use of anaferon – a drug containing ultra-high dilutions of affinity-purified antibodies to human IFN-γ as the active pharmaceutical ingredient – in the complex treatment of schizophrenia. Previously, it has been found that medication produces an immunomodulating effect: increases initially low IFN-γ levels, normalises elevated levels of IL-1β, optimises the Th1/Th2 balance of immune response, exerting ‘sparing’ therapeutic effect (16,17). The paper reports of the first ever experience of using anaferon as an additional drug in complex antipsychotic therapy of patients with schizophrenia, which is supported by a patent (20).…”